Evidence map›Paper›PMID 37111734›Full record

ReviewPharmaceutics2023

Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches.

Tanja Jesenko, Simona Kranjc Brezar, Maja Cemazar, Alice Biasin, Domenico Tierno, Bruna Scaggiante, Mario Grassi, Chiara Grassi, Barbara Dapas, Nhung Hai Truong and 7 more

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Article
  2. Review
  3. The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors.Medical oncology (Northwood, London, England) · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tanja JesenkoDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska 2, SI-1000 Ljubljana, Slovenia.ORCID 0000-0001-5883-1673
Simona Kranjc BrezarDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska 2, SI-1000 Ljubljana, Slovenia.
Maja CemazarDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska 2, SI-1000 Ljubljana, Slovenia.ORCID 0000-0002-1418-1928
Alice BiasinDepartment of Engineering and Architecture, Trieste University, via Valerio 6, I-34127 Trieste, Italy.ORCID 0000-0003-2841-1277
Domenico TiernoDepartment of Life Sciences, Cattinara University Hospital, Trieste University, Strada di Fiume 447, I-34149 Trieste, Italy.
Bruna ScaggianteDepartment of Life Sciences, Cattinara University Hospital, Trieste University, Strada di Fiume 447, I-34149 Trieste, Italy.ORCID 0000-0002-8662-138X
Mario GrassiDepartment of Engineering and Architecture, Trieste University, via Valerio 6, I-34127 Trieste, Italy.ORCID 0000-0002-3532-3200
Chiara GrassiDegree Course in Medicine, University of Trieste, I-34149 Trieste, Italy.
Barbara DapasDepartment of Life Sciences, Cattinara University Hospital, Trieste University, Strada di Fiume 447, I-34149 Trieste, Italy.
Nhung Hai TruongFaculty of Biology and Biotechnology, VNUHCM-University of Science, Ho Chi Minh City 70000, Vietnam.
Michela AbramiDepartment of Engineering and Architecture, Trieste University, via Valerio 6, I-34127 Trieste, Italy.
Fabrizio ZanconatiDepartment of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume, 447, I-34149 Trieste, Italy.
Deborah BonazzaDepartment of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume, 447, I-34149 Trieste, Italy.ORCID 0000-0002-5605-6711
Flavio RizzolioPathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, I-33081 Aviano, Italy.ORCID 0000-0002-3400-4363
Salvatore ParisiDepartment of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, I-30172 Venezia, Italy.
Giorgia PastorinPharmacy Department, National University of Singapore, Block S9, Level 15, 4 Science Drive 2, Singapore 117544, Singapore.ORCID 0000-0002-2568-0626
Gabriele GrassiDepartment of Life Sciences, Cattinara University Hospital, Trieste University, Strada di Fiume 447, I-34149 Trieste, Italy.ORCID 0000-0001-9704-6651

Funding

Italian Ministry of Foreign Affairs and International Cooperation grant number VN21GR01
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains a global health challenge, representing the third leading cause of cancer deaths worldwide. Although therapeutic advances have been made in the few last years, the prognosis remains poor. Thus, there is a dire need to develop novel therapeutic strategies. In this regard, two approaches can be considered: (1) the identification of tumor-targeted delivery systems and (2) the targeting of molecule(s) whose aberrant expression is confined to tumor cells. In this work, we focused on the second approach. Among the different kinds of possible target molecules, we discuss the potential therapeutic value of targeting non-coding RNAs (ncRNAs), which include micro interfering RNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). These molecules represent the most significant RNA transcripts in cells and can regulate many HCC features, including proliferation, apoptosis, invasion and metastasis. In the first part of the review, the main characteristics of HCC and ncRNAs are described. The involvement of ncRNAs in HCC is then presented over five sections: (a) miRNAs, (b) lncRNAs, (c) circRNAs, (d) ncRNAs and drug resistance and (e) ncRNAs and liver fibrosis. Overall, this work provides the reader with the most recent state-of-the-art approaches in this field, highlighting key trends and opportunities for more advanced and efficacious HCC treatments.

Indexed as

circular RNAshepatocellular carcinomalifer fibrosislong non-coding RNAsmicro interfering RNAs

Identifiers

PMID37111734
PMCPMC10145575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.